COMPASS Pathways(CMPS) - 2025 Q4 - Annual Results

Financial Performance - The net loss for Q4 2025 was $93.9 million, or $1.00 per share, compared to a net loss of $43.3 million, or $0.63 per share in Q4 2024[13] - For the full year 2025, net loss was $287.9 million, or $3.08 per share, compared to $155.1 million, or $2.30 per share in 2024[13] - The net loss for Q4 2025 was $93,878,000, compared to a net loss of $43,332,000 in Q4 2024, representing a significant increase of 116.7%[23] - The net loss per share attributable to ordinary shareholders for Q4 2025 was $1.00, compared to $0.63 in Q4 2024[23] - The company reported a comprehensive loss of $93,480,000 for Q4 2025, compared to a comprehensive loss of $42,984,000 in Q4 2024[23] Cash and Financing - Cash and cash equivalents as of December 31, 2025, were $149.6 million, down from $165.1 million as of December 31, 2024[13] - The company successfully raised $150 million in financing in February 2025, extending its cash runway into 2028[5] Research and Development - Research and development expenses for Q4 2025 were $29.9 million, a decrease from $32.1 million in Q4 2024[10] - Research and development expenses for the twelve months ended December 31, 2025, were $118,436,000, slightly down from $119,039,000 in 2024[23] Operating Expenses - General and administrative expenses for Q4 2025 were $16.0 million, slightly down from $16.3 million in Q4 2024[13] - Total operating expenses for Q4 2025 were $45,952,000, a decrease of 5.4% from $48,414,000 in Q4 2024[23] Other Financial Metrics - Total other (expense) income, net for Q4 2025 was $(50,660,000), a decline from $6,105,000 in Q4 2024[23] - The fair value change of warrant liabilities resulted in an expense of $38,163,000 for Q4 2025, with no such expense reported in Q4 2024[23] - Interest income for the twelve months ended December 31, 2025, was $7,182,000, down from $8,268,000 in 2024[23] - The income tax benefit for Q4 2025 was $2,734,000, compared to an expense of $1,023,000 in Q4 2024[23] Product Development and Regulatory Updates - COMP360 has shown a rapid onset of action with symptom reduction as early as the day after administration, and durability lasting at least 6 months after just one or two doses[11] - COMP360 is expected to fit seamlessly across over 7,300 treatment centers, which are rapidly growing in anticipation of its launch[11] - The FDA has accepted the IND application for COMP360 for PTSD, allowing the initiation of a Phase 2b/3 trial[11] - The company plans to meet with the FDA to confirm its NDA submission strategy, expecting to complete the submission in Q4 2026[6]